Activity of Matrix Metalloproteinases during Antimycobacterial Therapy in Mice with Simulated Tuberculous Inflammation

Matrix metalloproteinases are shown to be involved in the pathogenesis of tuberculosis inflammation. In the early stages of BCG-granuloma formation in mouse liver and lungs, the serum levels of matrix metalloproteinases 2 and 7 increased by 4.5 times and remained unchanged while the pathology develo...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2013-05, Vol.155 (1), p.34-36
Main Authors: Sumenkova, D. V., Russkikh, G. S., Poteryaeva, O. N., Polyakov, L. M., Panin, L. E.
Format: Article
Language:English
Subjects:
Animals
Antitubercular agents
Antitubercular Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Biophysics and Biochemistry
Cell Biology
Inflammation
Inflammation - drug therapy
Inflammation - metabolism
Internal Medicine
Isoniazid - therapeutic use
Laboratory Medicine
Male
Matrix Metalloproteinase 2 - blood
Matrix Metalloproteinase 7 - blood
Mice
Mice, Inbred CBA
Mycobacterium
Mycobacterium tuberculosis - drug effects
Pathology
Tuberculosis
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - enzymology
Tuberculosis, Pulmonary - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Matrix metalloproteinases are shown to be involved in the pathogenesis of tuberculosis inflammation. In the early stages of BCG-granuloma formation in mouse liver and lungs, the serum levels of matrix metalloproteinases 2 and 7 increased by 4.5 times and remained unchanged while the pathology developed. Antimycobacterial therapy with isoniazid reduced enzyme activity almost to the level of intact control. The decrease in activity of matrix metalloproteinases 2 and 7 that play the most prominent role in the development of destructive forms of tuberculosis is of great therapeutic importance.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-013-2073-9